Concord Biotech Limited vs Abbott India Limited
Last updated: 22 October 2026
MoneyDock presents a comparative analysis between two prominent players in the Indian pharmaceutical and biotechnology sector: Concord Biotech Limited (CONCORDBIO.NS) and Abbott India Limited (ABBOTINDIA.NS). Both companies operate in critical healthcare domains, offering diverse product portfolios. Concord Biotech, known for its focus on fermentation-based biopharmaceutical APIs, caters to a niche yet vital segment, while Abbott India, a subsidiary of the global healthcare giant, offers a wide range of pharmaceutical and nutritional products, commanding a significant market presence. This comparison aims to provide potential investors with a data-driven perspective on their current market standings, recent performance, and potential investment appeal, using only the provided financial metrics.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited (CONCORDBIO.NS) | Abbott India Limited (ABBOTINDIA.NS) |
|---|---|---|
| Current Price | ₹1270.00 | ₹25680.00 |
| 52-Week High | ₹1579.40 | ₹29025.00 |
| 52-Week Low | ₹1014.80 | ₹25180.00 |
| 1-Year Return | -6.66% | -7.91% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
From a valuation perspective, with both companies having a 'N/A' for Trailing P/E and Market Cap, a direct comparison on these widely used metrics is not possible based on the provided data. Investors would need to look at other fundamental metrics to assess their relative valuations.
Regarding returns, both companies have experienced negative 1-year returns. Concord Biotech (CONCORDBIO.NS) shows a 1-Year Return of -6.66%, which is marginally better than Abbott India (ABBOTINDIA.NS) at -7.91%. This indicates that Concord Biotech has slightly outperformed Abbott India in terms of mitigating losses over the past year.
For stability, we can look at the proximity of their current prices to their 52-week lows. Concord Biotech's current price of ₹1270.00 is significantly above its 52-week low of ₹1014.80, suggesting some recovery or resilience from its lowest point. Conversely, Abbott India's current price of ₹25680.00 is closer to its 52-week low of ₹25180.00, implying it is trading nearer to its yearly bottom. This could suggest that Concord Biotech has demonstrated relatively better price stability above its floor compared to Abbott India over the past year, or conversely, Abbott India is currently trading at a more attractive entry point if one believes in its recovery potential from its near-yearly low.
It's important to note that without P/E ratios and market capitalization figures, a comprehensive analysis of their market position and intrinsic value is limited. Investors should consider these numbers as part of a broader due diligence process, integrating qualitative factors such as management quality, competitive landscape, and future growth prospects.
MoneyDock Verdict
For Aggressive Investors: Given that both stocks have experienced negative returns, an aggressive investor might look for a company showing signs of a potential rebound from its lows. Abbott India, trading closer to its 52-week low, might present a 'buy the dip' opportunity if underlying fundamentals remain strong and a reversal is anticipated. Concord Biotech, while also down, is further from its low, potentially indicating less immediate upside from a pure price recovery perspective.
For Conservative Investors: The current data doesn't provide enough information on profitability (P/E) or market size (Market Cap) for a truly conservative assessment. Both stocks show negative 1-year returns, which conservative investors typically shy away from. However, if forced to choose based on relative performance, Concord Biotech's slightly better 1-year return (-6.66% vs -7.91%) might make it a marginally less risky option in a challenging market, as it has lost slightly less value.
For Long-Term SIP Investors: For long-term SIP investors, consistency and fundamental strength are key. Without Trailing P/E and Market Cap, it's hard to gauge intrinsic value and market leadership. Both are currently in a downturn phase, which could present averaging opportunities for SIP. However, the slightly less severe drop for Concord Biotech over the year might offer a marginally steadier entry for those looking to accumulate shares over time, assuming its long-term growth story remains intact. A deeper dive into business models and growth drivers is essential for SIP investors beyond these immediate price points.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.